Cargando…
Calcium channel modulation as a target in chronic pain control
Neuropathic pain remains poorly treated for large numbers of patients, and little progress has been made in developing novel classes of analgesics. To redress this issue, ziconotide (Prialt™) was developed and approved as a first‐in‐class synthetic version of ω‐conotoxin MVIIA, a peptide blocker of...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5980588/ https://www.ncbi.nlm.nih.gov/pubmed/28320042 http://dx.doi.org/10.1111/bph.13789 |
_version_ | 1783327902699356160 |
---|---|
author | Patel, Ryan Montagut‐Bordas, Carlota Dickenson, Anthony H |
author_facet | Patel, Ryan Montagut‐Bordas, Carlota Dickenson, Anthony H |
author_sort | Patel, Ryan |
collection | PubMed |
description | Neuropathic pain remains poorly treated for large numbers of patients, and little progress has been made in developing novel classes of analgesics. To redress this issue, ziconotide (Prialt™) was developed and approved as a first‐in‐class synthetic version of ω‐conotoxin MVIIA, a peptide blocker of Ca(v)2.2 channels. Unfortunately, the impracticalities of intrathecal delivery, low therapeutic index and severe neurological side effects associated with ziconotide have restricted its use to exceptional circumstances. Ziconotide exhibits no state or use‐dependent block of Ca(v)2.2 channels; activation state‐dependent blockers were hypothesized to circumvent the side effects of state‐independent blockers by selectively targeting high‐frequency firing of nociceptive neurones in chronic pain states, thus alleviating aberrant pain but not affecting normal sensory transduction. Unfortunately, numerous drugs, including state‐dependent calcium channel blockers, have displayed efficacy in preclinical models but have subsequently been disappointing in clinical trials. In recent years, it has become more widely acknowledged that trans‐aetiological sensory profiles exist amongst chronic pain patients and may indicate similar underlying mechanisms and drug sensitivities. Heterogeneity amongst patients, a reliance on stimulus‐evoked endpoints in preclinical studies and a failure to utilize translatable endpoints, all are likely to have contributed to negative clinical trial results. We provide an overview of how electrophysiological and operant‐based assays provide insight into sensory and affective aspects of pain in animal models and how these may relate to chronic pain patients in order to improve the bench‐to‐bedside translation of calcium channel modulators. LINKED ARTICLES: This article is part of a themed section on Recent Advances in Targeting Ion Channels to Treat Chronic Pain. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.12/issuetoc |
format | Online Article Text |
id | pubmed-5980588 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-59805882018-06-06 Calcium channel modulation as a target in chronic pain control Patel, Ryan Montagut‐Bordas, Carlota Dickenson, Anthony H Br J Pharmacol Themed Section: Review Articles Neuropathic pain remains poorly treated for large numbers of patients, and little progress has been made in developing novel classes of analgesics. To redress this issue, ziconotide (Prialt™) was developed and approved as a first‐in‐class synthetic version of ω‐conotoxin MVIIA, a peptide blocker of Ca(v)2.2 channels. Unfortunately, the impracticalities of intrathecal delivery, low therapeutic index and severe neurological side effects associated with ziconotide have restricted its use to exceptional circumstances. Ziconotide exhibits no state or use‐dependent block of Ca(v)2.2 channels; activation state‐dependent blockers were hypothesized to circumvent the side effects of state‐independent blockers by selectively targeting high‐frequency firing of nociceptive neurones in chronic pain states, thus alleviating aberrant pain but not affecting normal sensory transduction. Unfortunately, numerous drugs, including state‐dependent calcium channel blockers, have displayed efficacy in preclinical models but have subsequently been disappointing in clinical trials. In recent years, it has become more widely acknowledged that trans‐aetiological sensory profiles exist amongst chronic pain patients and may indicate similar underlying mechanisms and drug sensitivities. Heterogeneity amongst patients, a reliance on stimulus‐evoked endpoints in preclinical studies and a failure to utilize translatable endpoints, all are likely to have contributed to negative clinical trial results. We provide an overview of how electrophysiological and operant‐based assays provide insight into sensory and affective aspects of pain in animal models and how these may relate to chronic pain patients in order to improve the bench‐to‐bedside translation of calcium channel modulators. LINKED ARTICLES: This article is part of a themed section on Recent Advances in Targeting Ion Channels to Treat Chronic Pain. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.12/issuetoc John Wiley and Sons Inc. 2017-04-26 2018-06 /pmc/articles/PMC5980588/ /pubmed/28320042 http://dx.doi.org/10.1111/bph.13789 Text en © 2017 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Themed Section: Review Articles Patel, Ryan Montagut‐Bordas, Carlota Dickenson, Anthony H Calcium channel modulation as a target in chronic pain control |
title | Calcium channel modulation as a target in chronic pain control |
title_full | Calcium channel modulation as a target in chronic pain control |
title_fullStr | Calcium channel modulation as a target in chronic pain control |
title_full_unstemmed | Calcium channel modulation as a target in chronic pain control |
title_short | Calcium channel modulation as a target in chronic pain control |
title_sort | calcium channel modulation as a target in chronic pain control |
topic | Themed Section: Review Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5980588/ https://www.ncbi.nlm.nih.gov/pubmed/28320042 http://dx.doi.org/10.1111/bph.13789 |
work_keys_str_mv | AT patelryan calciumchannelmodulationasatargetinchronicpaincontrol AT montagutbordascarlota calciumchannelmodulationasatargetinchronicpaincontrol AT dickensonanthonyh calciumchannelmodulationasatargetinchronicpaincontrol |